Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mitochondrial dynamics imbalance in hepatocellular carcinoma: from molecular mechanisms to new strategies for targeted therapy.

Translational cancer research·2026

Same author

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Blood advances·2026

Same author

Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy.

Journal of comparative effectiveness research·2026

Same author

Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance.

Cell·2026

Same author

Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments and upon nutrient-starvation therapies.

Cell metabolism·2026

Same author

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Transplantation and cellular therapy·2026

Search research articles

Related Experiment Video

Updated: Apr 7, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

New immunotherapies targeting the PD-1 pathway.

Jordan M Chinai¹, Murali Janakiram², Fuxiang Chen³

¹Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.

Trends in Pharmacological Sciences

|July 12, 2015

Summary

The B7-CD28 pathway regulates T cell responses. Targeting programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) shows promise for treating cancers, infections, and autoimmune diseases.

Keywords:

PD-1 PD-L1 PD-L2 cancer immunotherapy viral infection

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Related Experiment Videos

Last Updated: Apr 7, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Area of Science:

Immunology
Molecular Biology
Oncology

Background:

The B7 family ligands interact with CD28 family receptors to control T cell activation, inflammation, and autoimmunity.
Programmed death-1 (PD-1), a CD28 family receptor, inhibits T cells and contributes to dysfunction in chronic infections and cancer.
The expression and signaling of PD-1 and its ligand PD-L1 are complex and under active investigation.

Purpose of the Study:

To review the emerging understanding of PD-1 and PD-L1 mechanisms.
To highlight the therapeutic potential of targeting the PD-1/PD-L1 pathway.

Main Methods:

Literature review of preclinical and clinical studies.
Analysis of emerging data on PD-1 and PD-L1 targeting strategies.

Main Results:

Clinical trials targeting PD-1/PD-L1 have yielded durable responses in some cancer patients.
Preclinical data suggest that targeting PD-1/PD-L1 can enhance T cell responses and viral clearance in chronic infections.
The PD-1/PD-L1 pathway is a promising target for autoimmune and inflammatory disorders.

Conclusions:

Targeting the PD-1/PD-L1 pathway represents a significant therapeutic strategy across oncology, infectious diseases, and autoimmune disorders.
Further research into the complex mechanisms of PD-1/PD-L1 signaling will refine therapeutic applications.